EA
CLDX icon

Emerald Advisers’s Celldex Therapeutics CLDX Stock Holding History

Emerald Advisers’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-456,202
Closed -$15.5M – 259
2024
Q3 		$15.5M Buy
456,202
+257,773
+130% +$9.82M 0.6% 68
2024
Q2 		$7.34M Sell
198,429
-13,606
-6% -$513K 0.31% 102
2024
Q1 		$8.9M Buy
+212,035
New +$8.71M 0.36% 100
2013
Q4 		– Sell
-30,375
Closed -$16.1M – 353
2013
Q3 		$16.1M Buy
30,375
+2,464
+9% +$845K 0.91% 25
2013
Q2 		$6.54M Buy
+27,911
New +$5.5M 0.4% 83

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Emerald Advisers's CLDX Position: Q4 2024 in Review

Emerald Advisers sold out of Celldex Therapeutics (CLDX) in Q4 2024, closing a stake of 456,202 shares — an estimated $15.5M sold.

Emerald Advisers first reported a position in CLDX in Q2 2013 and held it in 5 quarters. The position peaked at $16.1M in Q3 2013. 174 funds tracked by Wall St. Rank hold CLDX as of Q4 2024.

  • Emerald Advisers reported no remaining Celldex Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Emerald Advisers sold 456,202 Celldex Therapeutics shares in Q4 2024, an estimated $15.5M.
  • Emerald Advisers first reported a position in Celldex Therapeutics in Q2 2013 and held it in 5 quarters.
  • Emerald Advisers's Celldex Therapeutics position peaked at $16.1M in Q3 2013.
  • 174 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2024.

Based on Emerald Advisers's 13F filing for Q4 2024, filed 11 Feb 2025.